CN102625842A - 用于输送生物活性rna的组合物和方法 - Google Patents
用于输送生物活性rna的组合物和方法 Download PDFInfo
- Publication number
- CN102625842A CN102625842A CN2010800210226A CN201080021022A CN102625842A CN 102625842 A CN102625842 A CN 102625842A CN 2010800210226 A CN2010800210226 A CN 2010800210226A CN 201080021022 A CN201080021022 A CN 201080021022A CN 102625842 A CN102625842 A CN 102625842A
- Authority
- CN
- China
- Prior art keywords
- sequence
- rna
- cell
- biologically active
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16028809P | 2009-03-13 | 2009-03-13 | |
| US16028709P | 2009-03-13 | 2009-03-13 | |
| US61/160,288 | 2009-03-13 | ||
| US61/160,287 | 2009-03-13 | ||
| PCT/US2010/027365 WO2010105277A1 (en) | 2009-03-13 | 2010-03-15 | Compositions and methods for the delivery of biologically active rnas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102625842A true CN102625842A (zh) | 2012-08-01 |
Family
ID=42728852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800210226A Pending CN102625842A (zh) | 2009-03-13 | 2010-03-15 | 用于输送生物活性rna的组合物和方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8569065B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2406379A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2012520085A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110128345A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102625842A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010223888A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2755245A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010105277A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2525780B1 (en) | 2010-01-19 | 2022-09-07 | Northwestern University | Synthetic nanostructures including nucleic acids and/or other entities |
| US20130101512A1 (en) * | 2010-03-12 | 2013-04-25 | Chad A. Mirkin | Crosslinked polynucleotide structure |
| WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2857499A1 (en) | 2010-10-01 | 2015-04-08 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2012159164A1 (en) * | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| PT3682905T (pt) | 2011-10-03 | 2022-04-07 | Modernatx Inc | Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações |
| ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
| WO2013096958A1 (en) * | 2011-12-23 | 2013-06-27 | Egen, Inc. | Compositions and methods for the delivery of biologically active rnas |
| US20140371302A1 (en) * | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| PT2922554T (pt) | 2012-11-26 | 2022-06-28 | Modernatx Inc | Arn modificado nas porções terminais |
| WO2014144423A2 (en) * | 2013-03-15 | 2014-09-18 | Techulon Inc. | Antisense molecules for treatment of staphylococcus aureus infection |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015002956A1 (en) * | 2013-07-01 | 2015-01-08 | Ohio State Innovation Foundation | Exosome delivery system |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| US10568898B2 (en) | 2013-08-13 | 2020-02-25 | Northwestern University | Lipophilic nanoparticles for drug delivery |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
| EP3105254B1 (en) * | 2014-02-14 | 2019-11-20 | Symvivo Corporation | Hybrid proteins and uses thereof |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| EP3183007B1 (en) | 2014-08-19 | 2020-06-17 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| BR112017007012A2 (pt) | 2014-10-06 | 2018-03-06 | Exicure Inc | compostos anti-tnf |
| US9816080B2 (en) * | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
| US10078092B2 (en) | 2015-03-18 | 2018-09-18 | Northwestern University | Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules |
| AU2017212713B2 (en) | 2016-01-27 | 2023-01-19 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| US11639371B2 (en) * | 2016-02-17 | 2023-05-02 | The Chinese University Of Hong Kong | Peptidylic inhibitors of nucleolin (NCL) targeting CAG-repeat RNA toxicity and methods for reducing polyQ-mediated toxicity in polyQ diseases |
| JP2019515654A (ja) | 2016-03-16 | 2019-06-13 | ザ ジェイ. デヴィッド グラッドストーン インスティテューツ | 肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物 |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| MX2020000993A (es) | 2017-07-26 | 2020-07-22 | Oncorus Inc | Vectores virales oncolíticos y usos de estos. |
| WO2019133847A1 (en) | 2017-12-29 | 2019-07-04 | Oncorus, Inc. | Oncolytic viral delivery of therapeutic polypeptides |
| US20210139892A1 (en) * | 2018-07-05 | 2021-05-13 | The Regents Of The University Of California | Compositions and methods for delivery of rna to a cell |
| EP4034088A4 (en) | 2019-09-26 | 2023-10-11 | President and Fellows of Harvard College | Minimal arrestin domain containing protein 1 (arrdc1) constructs |
| WO2023244760A1 (en) * | 2022-06-15 | 2023-12-21 | Duke University | Protein library display systems and methods thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060101A2 (en) * | 2002-01-11 | 2003-07-24 | University Of Southern California | Gene delivery system and methods of use |
| CN1620464A (zh) * | 2001-12-20 | 2005-05-25 | 遗传和生物技术工程中心 | 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽 |
| US20050260756A1 (en) * | 2003-01-28 | 2005-11-24 | Troy Carol M | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
| CN1940074A (zh) * | 2006-08-07 | 2007-04-04 | 汪运山 | 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途 |
| WO2007126386A1 (en) * | 2006-05-03 | 2007-11-08 | Loetvall Jan Olof | Exosome transfer of nucleic acids to cells |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585263A (en) | 1994-05-20 | 1996-12-17 | University Of Alabama At Birmingham Research Foundation | Purified retroviral constitutive transport enhancer and its use to facilitate mRNA transport, and to produce recombinant, attenuated HIV |
| US6451592B1 (en) * | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| US20040241845A1 (en) * | 1998-05-22 | 2004-12-02 | Luc Desgroseillers | Mammalian staufen and use thereof |
| WO2000039311A1 (en) * | 1998-12-31 | 2000-07-06 | Advanced Research And Technology Institute | Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 |
| AU2001294872A1 (en) | 2000-09-28 | 2002-04-08 | Cellomics, Inc. | Methods and reagents for live-cell gene expression quantification |
| AU2003228301A1 (en) * | 2002-03-06 | 2003-09-22 | Rigel Pharmaceuticals, Inc. | Novel method for delivery and intracellular synthesis of sirna molecules |
| US20050074865A1 (en) | 2002-08-27 | 2005-04-07 | Compound Therapeutics, Inc. | Adzymes and uses thereof |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| GB0225788D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| WO2007092222A2 (en) * | 2006-02-02 | 2007-08-16 | Regenetech, Inc. | Method of characterizing a biologically active compound |
| JP2009532017A (ja) * | 2006-02-10 | 2009-09-10 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | PTD/CPPSへのdsRNA結合ドメイン融合体によるsiRNAの導入可能な送達 |
| EP2631295A3 (en) * | 2007-02-15 | 2014-01-01 | DSM IP Assets B.V. | A recombinant host cell for the production of a compound of interest |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
-
2010
- 2010-03-15 CA CA2755245A patent/CA2755245A1/en not_active Abandoned
- 2010-03-15 JP JP2011554275A patent/JP2012520085A/ja active Pending
- 2010-03-15 KR KR1020117024110A patent/KR20110128345A/ko not_active Ceased
- 2010-03-15 AU AU2010223888A patent/AU2010223888A1/en not_active Abandoned
- 2010-03-15 EP EP10751551A patent/EP2406379A4/en not_active Withdrawn
- 2010-03-15 WO PCT/US2010/027365 patent/WO2010105277A1/en not_active Ceased
- 2010-03-15 CN CN2010800210226A patent/CN102625842A/zh active Pending
- 2010-03-15 US US12/724,408 patent/US8569065B2/en active Active
-
2013
- 2013-03-11 US US13/793,961 patent/US20140005254A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1620464A (zh) * | 2001-12-20 | 2005-05-25 | 遗传和生物技术工程中心 | 用于治疗人乳头状瘤病毒相关性癌症和其他上皮性肿瘤的肽 |
| WO2003060101A2 (en) * | 2002-01-11 | 2003-07-24 | University Of Southern California | Gene delivery system and methods of use |
| US20050260756A1 (en) * | 2003-01-28 | 2005-11-24 | Troy Carol M | Complex for facilitating delivery of dsRNA into a cell and uses thereof |
| WO2007126386A1 (en) * | 2006-05-03 | 2007-11-08 | Loetvall Jan Olof | Exosome transfer of nucleic acids to cells |
| CN1940074A (zh) * | 2006-08-07 | 2007-04-04 | 汪运山 | 胃癌靶向AFP基因的siRNAs表达载体的构建、筛选及其用途 |
Non-Patent Citations (1)
| Title |
|---|
| TAI等: "Single-Shot, Multicycle Suicide Gene Therapy by Replication-Competent Retrovirus Vectors Achieves Long-Term Survival Benefit in Experimental Glioma", 《MOLECULAR THERAPY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US8569065B2 (en) | 2013-10-29 |
| JP2012520085A (ja) | 2012-09-06 |
| CA2755245A1 (en) | 2010-09-16 |
| KR20110128345A (ko) | 2011-11-29 |
| EP2406379A4 (en) | 2012-09-26 |
| WO2010105277A1 (en) | 2010-09-16 |
| US20140005254A1 (en) | 2014-01-02 |
| EP2406379A1 (en) | 2012-01-18 |
| US20100233141A1 (en) | 2010-09-16 |
| AU2010223888A1 (en) | 2011-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8569065B2 (en) | Compositions and methods for the delivery of biologically active RNAs | |
| JP7815327B2 (ja) | フソソーム組成物およびその使用 | |
| JP2024099582A (ja) | アルブミン遺伝子座からの導入遺伝子発現のための組成物及び方法 | |
| CA3120282A1 (en) | Fusosome compositions for hematopoietic stem cell delivery | |
| WO2021077000A1 (en) | Engineered muscle targeting compositions | |
| CA3120082A1 (en) | Fusosome compositions for cns delivery | |
| US20130164845A1 (en) | Compositions and Methods for the Delivery of Biologically Active RNAs | |
| WO2015002956A1 (en) | Exosome delivery system | |
| US20240408192A1 (en) | Modified paramyxoviridae attachment glycoproteins | |
| KR20230044420A (ko) | 바이러스 푸소좀을 생산하기 위한 방법 및 조성물 | |
| WO2023115039A2 (en) | Modified paramyxoviridae fusion glycoproteins | |
| CA3120103A1 (en) | Fusosome compositions for t cell delivery | |
| WO2024064838A1 (en) | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof | |
| JP2024505678A (ja) | 免疫療法のためのリンパ球活性化遺伝子3(lag3)組成物及び方法 | |
| EP4698665A1 (en) | Engineered protein g fusogens and related lipid particles and methods thereof | |
| TWI909459B (zh) | 工程化噬菌體顆粒及使用該噬菌體顆粒進行基因治療的方法 | |
| WO2025011467A1 (zh) | 工程化的哺乳动物基因写入系统 | |
| WO2024220574A1 (en) | Universal protein g fusogens and adapter systems thereof and related lipid particles and uses | |
| JP2024526878A (ja) | 調節されたウイルス送達システムおよびその使用 | |
| WO2023081926A1 (en) | Delta protocadherin therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: CLSN LABORATORIES, INC. Free format text: FORMER OWNER: EGEN INC. Effective date: 20150203 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20150203 Address after: Delaware Applicant after: CLSN LAB INC Address before: alabama Applicant before: Expression Genetics Inc. |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120801 |